Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
04:30pm, Monday, 09'th Aug 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGro
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2021 Results - Earnings Call Transcript
10:56pm, Thursday, 05'th Aug 2021
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2021 Results - Earnings Call Transcript
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
04:01pm, Thursday, 05'th Aug 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. “This i
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
CRISPR: 4 Emerging Players
09:06am, Wednesday, 30'th Jun 2021
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr
Sangamo's Hemophilia A Treatment: An Assessment
07:22am, Monday, 31'st May 2021
Sangamo and licensee Pfizer's SB-525 is competing with BioMarin's ValRox in hemophilia A. There are durability questions surrounding both drugs.
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
04:15pm, Monday, 24'th May 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript
11:29pm, Tuesday, 04'th May 2021
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
06:02pm, Tuesday, 04'th May 2021
Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
04:30pm, Monday, 03'rd May 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following inves
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
02:15pm, Tuesday, 23'rd Mar 2021
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
04:30pm, Wednesday, 17'th Mar 2021
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products (
Sangamo: Partnering A Path To The Future Of Medicine
04:58pm, Friday, 12'th Mar 2021
Genomic medicine collaborations are a valuable method of risk mitigation. They also are a source of funding which can be used to build a deeper pipeline. Sangamo is leveraging many pharmaceutical lead
Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?
07:00am, Friday, 05'th Mar 2021
The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call Transcript
11:45pm, Wednesday, 24'th Feb 2021
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call Transcript
